Article ID Journal Published Year Pages File Type
10908693 Leukemia Research 2014 7 Pages PDF
Abstract
The data confirmed that IFN α-2b benefited the patients with ET or PV, particularly for JAK2V617F+ mutation.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Preview
Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation
Authors
, , , , ,